Form 4: CVS Health Executive Reports Stock Transactions

CVS Health Corp. executive James David Clark reported transactions involving restricted stock units and common stock, including the surrender of shares for tax withholding.

Summary

• James David Clark, SVP, Cont & Chief Acct Officer at CVS Health Corp., reported transactions on March 31, 2026, and April 1, 2026.
• On March 31, 2026, 11,138 restricted stock units were acquired at a price of $71.82, bringing the total beneficial ownership of restricted stock to 35,539.
• On April 1, 2026, 3,262 shares of common stock were disposed of at a price of $72.49, resulting in a remaining beneficial ownership of 15,457 shares of common stock.
• The disposal of common stock on April 1, 2026, involved the surrender of shares to pay withholding taxes upon the vesting and settlement of restricted stock units.
• A stock option with an exercise price of $71.82 was acquired on March 31, 2026, with 11,976 shares underlying the option. This option becomes exercisable in three equal annual installments starting March 31, 2027, and expires on March 31, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine executive stock transactions and compensation-related events rather than significant strategic shifts or performance indicators.

Positives

• Acquisition of restricted stock units (11,138 shares) at a price of $71.82, indicating continued equity-based compensation for a key executive.
• Vesting and settlement of restricted stock units, leading to the acquisition of common stock.
• A stock option grant with a significant number of underlying shares (11,976) and a clear vesting schedule, suggesting long-term incentive alignment.

Negatives

• Surrender of 3,262 shares of common stock to cover tax withholding obligations upon vesting of restricted stock units, which reduces the executive's direct shareholding.

Future Outlook

The stock option and restricted stock units have a vesting schedule that extends to March 31, 2036, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported transactions, including the exercise of options and settlement of RSUs, are typical components of executive compensation packages in the pharmaceutical and healthcare retail industry, designed to align executive interests with shareholder value over the long term.

Stakeholder Impact

• Shareholders: The transactions reflect standard executive compensation practices and do not indicate any immediate impact on share supply or demand beyond routine adjustments for tax withholding.

Next Steps

• Vesting of remaining restricted stock units in two equal installments.
• Exercisability of stock options in two further equal annual installments commencing March 31, 2027.

Key Dates

Keywords

CVS Health, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Beneficial Ownership, Securities Exchange Act, Executive Compensation, Tax Withholding